4. Affective disorders in pregnant women has to be detected as soon as possible and treated with focused therapies in order to reduce the impact of PPD on offsprings and promote the welfare of both mother and baby.
Introduction
Perinatal depression, which includes major and minor depressive episodes, is one of the most common medical complications during pregnancy and postpartum (Committee on Obstetric Practice, 2015). As for other psychiatric disorders, perinatal depression is a complex condition, having a multi-dimensional phenotype and involving psychological/social factors beyond biological aspects (Martini et problems before conception. They reported that perinatal depressive symptoms are mostly preceded by mental health problems that begin before pregnancy, in adolescence or young adulthood, being women with a history of persisting common mental disorders before pregnancy a high-risk group. In light of their study they conclude that the window for considering preventive intervention for perinatal depression should be extended to the time before conception. A recent prospective mother-child study conducted in Greece analysed the relation between maternal trait anxiety and depression during pregnancy and the association with PPD, reporting the importance of antenatal maternal mental health and well being in identifying women at risk for PPD (Koutra et al., 2014) .
The effects of prenatal maternal stress impact mother and foetus/child bonding and infant growth in utero, furthermore, prolonged stress may result in hyperactivity of the stress system, altering glucocorticoid feedback, creating a vulnerability to addictive and mood disorders in offsprings (Brittain et al., 2015) . In the light of significant personal and social burden of PPD, purpose of the present review is to evaluate the state of art of the available biological biomarkers that could be useful in early detection of perinatal depression.
Methods
In order to provide an update overview, a research in main databases (Pubmed, ISIWEB of Knowledge, PsycINFO) was performed. Suitable articles were sourced from a comprehensive literature search and from references identified through other studies. All articles, concerning major/minor depression in pregnancy and post-partum were included. Keyword were "depression" matched with "pregnancy", "post partum", "perinatal" "biomarkers", "biochemistry", "immunology" "endocrinology", "genetic", "epigenetic", "clinical trials". Exclusion criteria were: animal studies, studies with different diagnosis (e.g. bipolar disorder), physiological studies, studies assessing rating scales, studies assessing the impact of pathological pregnancy on offsprings, neuroimaging studies.
The review covers findings from 1969 to 2015, last search was conducted on November 2015, even though most of articles have been produced in the last 10 years. After applying the inclusion and exclusion criteria, a total of 127 papers were included in the review, the majority of data being represented by endocrinological and immunological studies, while less studies have analysed biochemical and genetic pathways.
Genetic studies
As for other psychiatric disorders, PPD is, at least, partially genetic determined. The gene encoding BDNF is a strong candidate for PPD pathogenesis: its polymorphism (Val66Met) alters A genome-wide association study found that women with PPD displayed an increased sensitivity to estrogen signaling, confirming the previously proposed hypothesis of increased sex-steroid sensitivity as a susceptibility factor for PPD (Mehta et al., 2014) . Nine polymorphisms in estrogen receptor alpha gene (ESR1) were studied in postpartum women identified estrogen mediated epigenetic changes associated with PPD, identifying two biomarkers, HP1BP3 and TTC9B, which predicted PPD in a sample of high risk women. In addition, the authors found a decrease in the ratio of monocytes to lymphocytes plus granulocytes in the antenatally depressed women in relation with HP1BP3 methylation status, thus supporting the hypothesis of a higher sensitivity to estrogens in women at risk for PPD. A cross-species translational study evaluating DNA methylation, confirmed the link of the two biomarker loci, HP1BP3 and TTC9B, with PPD onset with an area under the curve (AUC) of 0.87 in antenatally euthymic women and 0.12 in a replication sample of antenatally depressed women, thus supporting the involvement of altered sensitivity to estrogen-mediated epigenetic alterations in PPD etiology (Guintivano et al., 2014) . Recently Osborne and colleagues (2015) replicated Kaminsky/Guintivano findings (2014), in particular TTC9B and HP1BP3 DNA methylation have been associated with estradiol and allopregnanolone levels over the course of pregnancy, suggesting that epigenetic variation at these loci may be important for mediating hormonal sensitivity and possibly predicting PPD onset.
Maternal RNA was collected in order to analyse the pheripheral expression of glucorticoid receptor (GR) co-chaperone genes in women with a lifetime history of mood or anxiety disorder. This study reported that prenatal depressive symptoms appear to be associated with altered regulation of GR sensitivity, possibly being a biomarker for depressive symptoms during pregnancy (Katz et al., 2012) . A prospective study found that PPD risk correlated significantly with 17β-estradiol (E2) induced DNA methylation change, suggesting an enhanced sensitivity to estrogen-based DNA methylation reprogramming in women at risk for PPD (Guintivano et al., 2014) . A prospective study investigated the association of genetic variants in the glucocorticoid receptor (GR, NR3C1) and corticotropin releasing hormone receptor 1 were assayed from DNA extracted during pregnancy: an interaction was found between rs53576 and methylation in the OXTR gene amongst women who did not have depression prenatally but developed PPD. Those women with GG genotype showed 2.63 greater odds of PPD for every 10% increase in methylation level, whereas methylation was unrelated to PPD amongst "A" carriers; OXTR could be a susceptible genotype play a contributory role in the etiology of PPD (Bell et al., 2015) .
A prospective pregnancy cohort study examined associations between maternal depressive symptoms and placental expression of genes involved in glucocorticoid and serotonin transfer, reporting that altered placental function as a potential gestational-age-specific marker of PPD risk (Reynolds et al., 2015) . A cohort study evaluated single nucleotide polymorphisms (SNPs) of tryptophan hydroxylase 2 (TPH2) gene in pregnant and postpartum women. The haplotype block in the promoter region of TPH2 showed significant associations with depression both in pregnancy and postpartum. Furthermore, a haplotype block in intron 8, had an influence on depression scores during pregnancy, but not after birth; the effect of TPH2 haplotypes on EPDS values was strongest during pregnancy and 6 months after birth (Fasching et For a summary of the reviewed studied observing changes in genetic/epigenetic pathways in perinatal depression see Table 1 .
Biochemical studies
Depressive symptoms and serum zinc/magnesium levels were determined in antepartum and postpartum, revealing a relationship between severity of depressive symptoms and decreased serum zinc (but not magnesium) concentration in PPD (Wójcik et al., 2006) For a summary of the reviewed studied observing changes in biochemical pathways in perinatal depression see Table 2 .
Immunological studies
Immune system may contribute to PPD onset, according to psychoneuroimmunology A longitudinal preliminary study with high risk PPD women measured serum C-reactive protein and IL-6, as well as tryptophan, kynurenine, and the kynurenine/tryptophan ratio. Creactive protein levels were found to be positively related to atypical and total depression scores in the prepartum period and with atypical depression scores in the early postpartum period, while tryptophan was found to be negatively associated with total depression scores (Scrandis et al.,
2008).
For a summary of the reviewed studied observing changes in immunological pathways in perinatal depression see Table 3 .
Endocrinological studies
Maternal women with major depression history and 14 women with negative psychiatric history. Subjects with prior depressions had significantly higher T3, T4, TSH and cortisol levels during the puerperium, while subjects with higher levels of postpartum dysphoria had lower T4 and free T4 levels as well as higher T3 uptake at 38 weeks of pregnancy, higher cortisol levels during the puerperium (Pedersen et al., 1993).
Oxytocin (OT) system contribute to parental, romantic and filial attachment in humans. For a summary of the reviewed studied observing changes in endocrinological pathways in perinatal depression see Table 4 .
Conclusions
In 1998 54. Iliadis, S.I., Comasco, E., Sylvén, S., Hellgren, C., Sundström Poromaa, I., Skalkidou, A,.
Prenatal and Postpartum Evening Salivary Cortisol Levels in Association with
Peripartum Depressive Symptoms. PLoS One 10 (8), e0135471. Decrease in the ratio of monocytes to lymphocytes and granulocytes in the antenatally depressed women that correlated with HP1BP3 DNA methylation status.
Licinio, 2010
Gene expression from peripheral blood mononuclear cells Downregulation of transcription after delivery, with differential immune activation, decreased transcriptional engagement in cell proliferation, and DNA replication and repair processes Osborne et al., 2015 TTC9B and HP1BP3 DNA methylation association to the change in estradiol and allopregnanolone over the course of pregnancy Epigenetic variation at these loci may be important for mediating hormonal sensitivity and possibly predicting PPD onset. Univariate associations between prenatal depression and measures of blood fatty acids. Such associations were not found post-natally, but different associations were quantified between EPDS-diagnosed depression and total omega-6, total omega-3 and EPA omega-3. Association between a low omega-3 index in late pregnancy and higher depression score three months postpartum.
Tab. 2 Biochemical studies
Inverse correlation between DPA content, DHA content, omega-3 index, omega-3/omega-6 ratio, total HUFA score, omega-3 HUFA score with the EPDS score. Sallis, 2014 Association between levels of two omega-3 FAs (DHA and EPA) and perinatal onset depression, antenatal depression and postnatal depression.
A weak positive association was found with FAs and PPD. Subjects with prior depressions had significantly higher T3, T4, TSH and cortisol levels during the puerperium. Lower T4 and free T4 levels as well as higher T3 uptake at 38 weeks of pregnancy, higher cortisol levels during the puerperium in subjects with higher levels of postpartum dysphoria. Kuijpens, 2001 310 pregnant women prospective observational study TSH, free thyroxine and TPOAb testing, depression assessment according to the Research Diagnostic Criteria (RDC).
After the exclusion of women who were depressed at 12 weeks gestation, the presence of TPOAbs during early pregnancy was still found to be associated with the development of PPD; after exclusion of women who had had depression in earlier life, TPOAb during early gestation was still associated with PPD. Bloch, 2000 Gonadotropin-releasing hormone agonist leuprolide acetate, adding back supraphysiologic doses of estradiol and progesterone for 8 weeks, and then withdrawing both steroids under double-blind conditions.
Five of the eight women with a history of PPD (62.5%) and none of the eight women in the comparison group developed significant mood symptoms during the withdrawal period. Increase in depressive symptoms in women with a history of PPD. Women developping PPD symptoms had higher levels of beta-endorphin throughout pregnancy compared to women without PPD symptoms.
